Specifically, Chen and coworkers showed, by treating lung cancer cells for 24 h with different astragalin doses (2.5, 5, 10, 20 μg/mL), that this compound inhibits NF-κB/p65 nuclear translocation and IκBa degradation in a dose-dependent manner. Here, NFKB1 is linked to lung carcinoma.